![](https://www.rickilewis.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUJlQVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--882ec6b5c0405b6e3deef21338e79e9f9b1fc7c5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFMZ0FXa0M0QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--d00c0b801be2eac628730b2b4ffb891cbdd69dfe/BRCA-640x320_2.jpg)
The news release Monday morning grabbed my attention:
“Study finds wide gap in quality ofBRCA1/2variant classification between Myriad Genetics and a common public database.”
Myriad Genetics had been exclusively providing the tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering the tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it’s proprietary. Read More
“Study finds wide gap in quality ofBRCA1/2variant classification between Myriad Genetics and a common public database.”
Myriad Genetics had been exclusively providing the tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering the tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it’s proprietary. Read More